It first gained approval in Canada in 2015. MSD previously received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for sotatercept, branded as Winrevair, for the ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States ... the successful launch of WINREVAIR and strong performance of our Animal Health business,” said ...

Merck, known as MSD outside of the United States and Canada, announced the phase 3 HYPERION study evaluating Winrevair (sotatercept-csrk) versus placebo (both in combination with background therapy) ...

MSD has put a stop to its Phase III HYPERION study investigating its pulmonary arterial hypertension (PAH) treatment Winrevair after the therapy provided positive results from another Phase III trial.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the Phase 3 HYPERION study evaluating WINREVAIR (sotatercept-csrk) versus placebo (both in combination with ...

Winrevair (sotatercept), a treatment for pulmonary arterial hypertension (PAH), has emerged as a promising candidate with the potential to reshape the PAH treatment landscape. Analysts are eagerly ...

Adverse events have led Keros to abandon a phase 2 trial of pulmonary arterial hypertension drug cibotacept, a would-be rival to MSD's Winrevair. Join the conversation, on Tuesday 28th January ...

MSD has kicked off a new phase 3 trial of its ... One of those haematology drugs – Winrevair for pulmonary artery hypertension (PAH), which was acquired as part of the company's $11.5 billion ...